High-grade and low-grade pelvic serous neoplasms demonstrate differential p53 immunoreactivity in peritoneal washings

Acta Cytologica

Volumn 55, Issue 1, 2010, Pages 79-84

  Chang, Martin C ^a,b   Cibas, Edmund S ^a,b   Crum, Christopher P ^a,b   Kindelberger, David W ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cytopathology; Immunocytochemistry; Ovarian cancer; p53 antigen; Serous borderline tumors; Serous carcinoma

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL COUNT; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; EPITHELIOID CELL; FEMALE; HIGH GRADE PELVIS SEROUS CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; LOW GRADE PELVIS SEROUS NEOPLASM; PELVIS TUMOR; PERITONEUM LAVAGE; PRIORITY JOURNAL;

EID: 79953793540     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000320862     Document Type: Article

References (27)

1. Lee KR, Tavassoli FA, Prat J, et al: Surface epithelial-stromal tumours; in Tavassoli FA, Devilee P (eds): WHO Classification of Tumors, Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France, IARC Press, 2003, pp 117-145.
2. Malpica A, Deavers MT, Lu K, et al: Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28: 496-504.
3. Malpica A, Deavers MT, Tornos C, et al: Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 2007; 31: 1168-1174.
4. Teneriello MG, Ebina M, Linnoila RI, et al: p53 and K-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993; 53: 3103-3108.
5. Seidman JD, Kurman RJ: Subclassification of serous borderline tumors of the ovary into benign and malignant types: a clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996; 20: 1331-1345.
6. Singer G, Oldt R III, Cohen Y, et al: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95: 484-486.
7. Bonome T, Lee J-Y, Park D-C, et al: Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005; 65: 10602-10612.
8. Plaxe SC: Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol 2008; 198: 459.e1-459.e9.
9. Ho C-L, Kurman RJ, Dehari R, Wang TL, Shih IeM: Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004; 64: 6915-6918.
10. Dalrymple JC, Bannatyne P, Russell P, et al: Extraovarian peritoneal serous papillary carcinoma: a clinicopathologic study of 31 cases. Cancer 1989; 64: 110-115.
11. Shih IeM, Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-1518.
12. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29: 218-224.
13. Cheung TK, Cunningham JM, Webb MJ, Goellner JR, Kovach JS: Detection of p53 antigen expression in cytologic preparations of ovarian carcinomas. Anticancer Res 1994; 14: 1335-1338.
14. Klemi PJ, Takahashi S, Joensuu H, Kiilholma P, Narimatsu E, Mori M: Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 1994; 13: 228-233.
15. Reles A, Schmider A, Press MF, et al: Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol 1996; 122: 489-494.
16. Geisler JP, Geisler HE, Wiemann MC, Givens SS, Zhou Z, Miller GA: Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 1997; 66: 435-438.
17. Eltabbakh GH, Belinson JL, Kennedy AW, et al: p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 1997; 80: 892-898.
18. Lee Y, Miron A, Drapkin R, et al: A candidate precursor to serous carcinoma that originates in the fallopian tube. J Pathol 2007; 211: 26-35.
19. Jarboe E, Folkins A, Nucci MR, et al: Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2007; 1-9.
20. Folkins AK, Jarboe EA, Saleemuddin A: A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008; 109: 168-173.
21. Oates J, Edwards C: HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000; 36: 341-347.
22. Zuna RE, Behrens A: Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients. J Natl Cancer Inst 1996; 88: 980-987.
23. Fadare O, Mariappan MR, Wang S, Hileeto D, McAlpine J, Rimm DL: The histologic subtype of ovarian tumors affects the detection rate by pelvic washings. Cancer 2004; 102: 150-156.
24. Skilling JS, Sood A, Niemann T, Lager DJ, Buller RE: An abundance of p53 null mutations in ovarian carcinoma. Oncogene 1996; 13: 117-123.
25. Meinhold-Heerlein I, Ninci E, Ikenberg H, et al: Evaluation of methods to detect p53 mutations in ovarian cancer. Oncology 2001; 60: 176-188.
26. Walts AE, Said JW, Koeffler HP: Is immunoreactivity for p53 useful in distinguishing benign from malignant effusions? Localization of p53 gene product in benign mesothelial and adenocarcinoma cells. Mod Pathol 1994; 7: 462-468.
27. Stoetzer OJ, Munker R, Darsow M, Willmans W: P53-immunoreactive cells in benign and malignant effusions: diagnostic value using a panel of monoclonal antibodies and comparison with CEA-staining. Oncol Rep 1999; 6: 455-458.